Spyre Therapeutics Raises $350 Million as Short Sellers Bet $1.14 Billion Against Its Pipeline

Waltham, Sunday, 18 October 2026.
Biopharmaceutical firm Spyre Therapeutics (NASDAQ: SYRE) recently completed a $350 million follow-on equity offering to fund its long-acting antibody therapies for inflammatory bowel disease. Despite an impressive year-to-date share price surge of over 160%, market sentiment remains fiercely divided in October 2026. Most intriguingly, short sellers have accumulated a massive $1.14 billion position against the company—pushing short interest to 17.33% of its public float—setting the stage for significant volatility and a potential short squeeze. While recent insider sales totaling nearly $16.9 million reflect internal caution, prominent financial analysts reiterate a bullish long-term outlook on the firm’s advanced combination therapies. Backed by a refreshed capital balance and ongoing mid-stage trials targeting ulcerative colitis, Spyre stands at a high-stakes crossroads between heavy market skepticism and drug development potential.